CVR: 36428023
DKK -49,353
Gross profit
Net result: DKK -49,353
PETER BANG HOLDING ApS, LARS NYENSTAD ApS
2 more
CVR · view ownership and management
Owner registered: LARS NYENSTAD ApS
CVR · 27/03/2025
View the full event history
PULMOPHARMA ApS is a Danish company of the type Anpartsselskab based in Ebeltoft, founded in 2014. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Dan Mønster Nielsen. The company's owners include PETER BANG HOLDING ApS, LARS NYENSTAD ApS and BENDIX-HOLDING ApS. In 2025, the company reported a gross profit of DKK -49,353 and a net result of DKK -49,353 compared with DKK -20,499 the year before. Equity in the 2025 report amounted to DKK 11,436,934.
Selskabets formål er udvikling af et nyt medicinsk præparat.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -49 t. | -49 t. | 13.6 mio. | 11.4 mio. | 0 | |
| 202401/01/2024 – 31/12/2024 | -20 t. | -20 t. | 9.3 mio. | 7.4 mio. | 0 | |
| 202301/01/2023 – 31/12/2023 | -47 t. | -47 t. | 8.9 mio. | 7.4 mio. | 0 | |
| 202201/01/2022 – 31/12/2022 | -56 t. | -63 t. | 5 mio. | 3.4 mio. | 0 | |
| 202101/01/2021 – 31/12/2021 | -80 t. | -93 t. | 4 mio. | 3.5 mio. | 0 | |
| 202001/01/2020 – 31/12/2020 | -1 t. | -19 t. | 80 t. | -395 t. | 1 | |
| 201901/01/2019 – 31/12/2019 | -9 t. | -26 t. | 80 t. | -376 t. | - | |
| 201801/01/2018 – 31/12/2018 | -292 t. | -224 t. | 75 t. | -350 t. | - | |
| 201701/01/2017 – 31/12/2017 | -120 t. | -123 t. | 30 t. | -126 t. | - | |
| 201601/01/2016 – 31/12/2016 | 0 | 0 | 80 | -3 t. | - |
Compared to 1.041 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationPULMOPHARMA ApS was founded on 1 November 2014.
PULMOPHARMA ApS is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (industry code 721000).
The owners of PULMOPHARMA ApS include PETER BANG HOLDING ApS, LARS NYENSTAD ApS and BENDIX-HOLDING ApS.
In 2025, PULMOPHARMA ApS reported a gross profit of DKK -49,353.
The management of PULMOPHARMA ApS consists of Dan Mønster Nielsen.
PULMOPHARMA ApS is located at c/o Dan Mønster Nielsen, Bøgebjerg 2 2. 4, 8400 Ebeltoft.
Claim this page to add your logo and social links. Free to get started.
PULMOPHARMA ApS has published its annual report for 2025. Gross profit came to DKK -49,353, and the net result was DKK -49,353.
PULMOPHARMA ApS has published its annual report for 2024. Gross profit came to DKK -20,499, and the net result was DKK -20,499.
As of March 27, 2025, LARS NYENSTAD ApS is registered as an owner of PULMOPHARMA ApS with an ownership share of 20%.
As of March 27, 2025, BENDIX-HOLDING ApS is registered as an owner of PULMOPHARMA ApS with an ownership share of 20%.
As of March 27, 2025, LouMar ApS is registered as an owner of PULMOPHARMA ApS with an ownership share of 20%.
PULMOPHARMA ApS has published its annual report for 2023. Gross profit came to DKK -47,300, and the net result was DKK -47,300.
PULMOPHARMA ApS has published its annual report for 2022. Gross profit came to DKK -56,496, and the net result was DKK -62,830.
As of April 11, 2023, PETER BANG HOLDING ApS is registered as an owner of PULMOPHARMA ApS with an ownership share of 25%.
PULMOPHARMA ApS has published its annual report for 2021. Gross profit came to DKK -80,380, and the net result was DKK -93,103.
PULMOPHARMA ApS has published its annual report for 2020. Gross profit came to DKK -1,060, and the net result was DKK -18,958.
As of May 28, 2021, Per Bendix Jeppesen has joined the board of directors of PULMOPHARMA ApS.
As of May 28, 2021, Dan Mønster Nielsen has joined the board of directors of PULMOPHARMA ApS.
As of May 28, 2021, Peter Frithjof Bang has joined the board of directors of PULMOPHARMA ApS.
As of May 28, 2021, Torben Ballegaard Sørensen has joined the board of directors of PULMOPHARMA ApS.
PULMOPHARMA ApS has published its annual report for 2019. Gross profit came to DKK -8,735, and the net result was DKK -25,905.
PULMOPHARMA ApS has published its annual report for 2018. Gross profit came to DKK -292,381, and the net result was DKK -223,907.
PULMOPHARMA ApS has published its annual report for 2017. Gross profit came to DKK -120,467, and the net result was DKK -123,491.
As of January 4, 2018, Per Bendix Jeppesen has stepped down as director of PULMOPHARMA ApS.
As of January 4, 2018, Torben Ballegaard Sørensen has stepped down as director of PULMOPHARMA ApS.
PULMOPHARMA ApS has published its annual report for 2016. Gross profit came to DKK 0, and the net result was DKK 0.
PULMOPHARMA ApS has published its interim report for the period November 1, 2014 – December 31, 2015.
As of November 1, 2014, Per Bendix Jeppesen is registered as director of PULMOPHARMA ApS.
As of November 1, 2014, Dan Mønster Nielsen is registered as director of PULMOPHARMA ApS.
As of November 1, 2014, Torben Ballegaard Sørensen is registered as director of PULMOPHARMA ApS.
PULMOPHARMA ApS was founded on November 1, 2014.
Companies in the same industry and area
CVR 32294715
CVR 32879454
CVR 40769374
CVR 38301284
CVR 25514386
